Loading...
About 70% of asthma patients have “type 2” disease with eosinophilic or allergic inflammation. For such patients whose asthma is not controlled by inhaled corticosteroids and long-acting β-agonists, several biologics are available that target mediators of type 2 inflammation: Mepolizumab, benralizumab, and reslizumab target interleukin (IL)-5; dupilumab targets IL-4/IL-13; omalizumab targets IgE; and tezepelumab targets thymic stromal lymphopoietin. Because we have no head-to-head data to compare these drugs, researchers analyzed data from U.S. patients (age, ≥12) who started dupilumab, benralizumab, or mepolizumab (≈1800 patients in each group) within 1 year of asthma diagnoses.
Incidence of exacerbations within 1 year of starting treatment…